United States: How FDA Differs From CMS In Clinical Lab Test Oversight

Law360, New York (March 14, 2013, 12:36 PM ET) - The U.S. Food and Drug Administration has previously announced an interest in regulating diagnostic tests used in providing personalized medicine clinical care. Interested stakeholders such as the American Clinical Laboratory Association, the College of American Pathologists and the Association for Molecular Pathology, have weighed in on whether the FDA can and should expand its jurisdiction to laboratory-developed tests (LDTs) performed by clinical laboratories.

To the end of understanding the issues and concerns of stakeholders and the public, the Personalized Medicine Coalition (PMC) recently issued a white paper reporting on the regulatory landscape for personalized medicine tests and services in U.S. clinical practice. The report "Personalized Medicine Regulation: Pathways for Oversight of Diagnostics" (available here) explains the current regulatory oversight of diagnostic tests and, in particular, LDTs, and contrasts their regulation with regulation of certain diagnostic tests by the FDA.

Current Regulatory Framework

Personalized medicine relies on the accurate analysis of a patient's clinical symptoms and/or genome. Diagnostic medicine is integral to the basic tenet of personalized medicine - finding the right treatment for the right patient at the right time. Thus, the safe and appropriate use of reliable and valid diagnostic tests is central to the successful adoption of personalized medicine.

The report notes that two separate agencies in the U.S. Department of Health and Human Services oversee personalized medicine products and services in the United States. The FDA regulates pharmaceutical products, biological products and medical devices used in patient care, including care that is considered personalized medicine.

Clinical laboratories that perform diagnostic medicine such as genetic analysis (typically called LDTs) are under the jurisdiction of the Centers for Medicare and Medicaid Services, pursuant to the Clinical Laboratory Improvement Amendments (CLIA). CMS certification currently is required before clinical laboratories can generally perform diagnostic tests and interpret and report results to health care providers.

Comparison of FDA and CMS Regulation of Diagnostic Tests

The PMC report reviews in detail the structure of the FDA and the CMS and the current oversight of LDTs by each agency. The PMC report notes five key ways the FDA's approach to regulating the manufacture and distribution of diagnostic medical devices differs from the CMS' approach to regulating diagnostic test services performed by laboratories:

Requirements for Evidence of Analytical and Clinical Validity

The PMC report notes that the FDA regulated tests (termed "in vitro diagnostics" or "IVDs") require clinical evidence to support the intended use and indications for the test (i.e., the test's ability to identify or predict the disorder of interest) and require review of analytical performance.

CLIA regulations for LDTs require a demonstration of laboratory performance and that the test methodologies selected have the capability of providing quality results. However, this information generally does not require review by an external body prior to the lab offering the test unless required by state law.

Time to Market

Because the FDA requires detailed clinical review of IVDs prior to market, the premarket review process for tests regulated by the FDA can take several months to years. The FDA can also require approval or clearance of new premarket submissions if changes are made to diagnostic tests after FDA approval or clearance. Laboratories using FDA-approved tests must also comply with CLIA quality controls. In contrast, LDTs do not require review or approval from an outside body prior to clinical use, again unless required by state law.

Labeling and Promotion

The FDA permits the promotion of regulated IVDs only in accordance with their cleared or approved intended uses. The CMS, in contrast, does not restrict the clinical claims for LDTs developed by CLIA labs. However, advertisement of clinical claims for LDTs is subject to oversight by a separate federal agency - the Federal Trade Commission and applicable state laws - and must carry a disclaimer that the test has not been cleared or approved by the FDA.

Quality Programs and Post-Market Capabilities

The quality programs for FDA-regulated IVDs and LDTs have different elements that may or may not overlap. In brief, FDA-regulated tests must utilized design controls for development and validation of diagnostic assays and other process controls, which are not required for LDTs.

LDTs, in contrast, need only to follow good laboratory practice standards and process requirements. Also, manufacturers of IVDs are subject to periodic FDA inspection while CLIA laboratories generally are subject only to their own quality control inspections for compliance with CLIA regulations.

FDA regulations also require reporting of adverse events associated with a product, and the manufacturer must have a process for implementing a product recall. CLIA regulations, in contrast, simply require policies and procedures to monitor, access and correct problems uncovered during use of the tests.

Financial Consequences

CLIA laboratories pay a user fee for initial laboratory certification and biennial recertification based on the volume of clinical testing. Manufacturers of IVDs pay fees for diagnostic premarket submissions and pay an annual establishment registration fee.

As of Jan. 1, of 2013, FDA-regulated tests (with a few exceptions) are subject to a 2.3-percent federal excise tax pursuant to the Patient Protection and Affordable Care Act. If LDTs were to be regulated by the FDA, LDTs would likely be subject to the FDA fees and excise tax in addition to CLIA fees.

Recommendations and Conclusion

The PMC report indicates that there are significant differences of opinion among stakeholders on the optimal level of regulation and oversight of LDTs, especially when the outcome of an LDT impacts pharmacological intervention. Some stakeholders view FDA regulation of LDTs, in addition to CMS regulation, as creating a disproportionate burden on laboratories that would slow innovation to the detriment of physicians and patients and would unnecessarily increase the cost of providing laboratory services.

Other stakeholders opine that the current regulatory oversight of LDTs is insufficient in view of the increased complexity of the tests. They argue that a risk-based FDA approach can sustain and promote innovation, while benefiting patient safety.

The PMC report closes by noting, "[w]hether the various stakeholders working with Congress, the interested government agencies, and other authoritative bodies can reach an understanding on the optimal path forward remains to be seen."

Those institutions or individuals involved in LDTs would be well advised to closely monitor ongoing discussions of this topic in the coming months and provide their feedback during the public comment period for any proposed regulations governing LDTs.

Previously published by Law360

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.